Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia

Back to Search
Print
Bookmark Trial

NCT00330785

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Calgary, Alberta, T2N 2T8, Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension, Dyslipidemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-80 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who are above target LDL-C and BP who are eligible for treatment

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- High liver enzymes

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Hypertension, DyslipidemiaCaduet in an Untreated Subject Population
NCT00332761
  1. Jonesboro, Arkansas
  2. Little Rock, Arkansas
  3. Garden Grove, California
  4. Long Beach, California
  5. Tustin, California
  6. Aventura, Florida
  7. Ft. Lauderdale, Florida
  8. Miami, Florida
  9. Pembroke Pines, Florida
  10. Atlanta, Georgia
  11. Decatur, Georgia
  12. Bossier City, Louisiana
  13. Fair Haven, Michigan
  14. Livonia, Michigan
  15. Jackson, Mississippi
  16. Jackson, Mississippi
  17. Excelsior Springs, Missouri
  18. Berlin, New Jersey
  19. Elizabeth, New Jersey
  20. Princeton, New Jersey
  21. South Bound Brook, New Jersey
  22. Binghamton, New York
  23. Monroe, North Carolina
  24. Winston-Salem, North Carolina
  25. Cincinnati, Ohio
  26. Dayton, Ohio
  27. Eugene, Oregon
  28. Bensalem, Pennsylvania
  29. Kingsport, Tennessee
  30. Beaumont, Texas
  31. Colleyville, Texas
  32. Houston, Texas
  33. Temple, Texas
  34. Norfolk, Virginia
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Hypertension, DyslipidemiaOpen Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
NCT00330785
  1. Calgary, Alberta
  2. Calgary, Alberta
  3. Calgary, Alberta
  4. Calgary, Alberta
  5. Calgary, Alberta
  6. Red Deer, Alberta
  7. Campbell River, British Columbia
  8. Chilliwack, British Columbia
  9. New Westminster, British Columbia
  10. North Vancouver, British Columbia
  11. Quesnel, British Columbia
  12. Vancouver, British Columbia
  13. Vancouver, British Columbia
  14. Vancouver, British Columbia
  15. Vancouver, British Columbia
  16. Vancouver, British Columbia
  17. Winnipeg, Manitoba
  18. Winnipeg, Manitoba
  19. Antigonish, Nova Scotia
  20. Digby, Nova Scotia
  21. Halifax, Nova Scotia
  22. Halifax, Nova Scotia
  23. Truro, Nova Scotia
  24. Wolfville, Nova Scotia
  25. Alymer, Ontario
  26. Corunna, Ontario
  27. Exeter, Ontario
  28. Hamilton, Ontario
  29. Kingston, Ontario
  30. London, Ontario
  31. London, Ontario
  32. London, Ontario
  33. London, Ontario
  34. London, Ontario
  35. London, Ontario
  36. London, Ontario
  37. North York, Ontario
  38. North York, Ontario
  39. Oshawa, Ontario
  40. Oshawa, Ontario
  41. Peterborough, Ontario
  42. Sarnia, Ontario
  43. Toronto, Ontario
  44. Toronto, Ontario
  45. Toronto, Ontario
  46. Toronto, Ontario
  47. Waterloo, Ontario
  48. Weston, Ontario
  49. Whitby, Ontario
  50. Charlottetown, Prince Edward Island
  51. Bonaventure, Quebec
  52. Chomedy, Quebec
  53. Gatineau, Quebec
  54. Granby, Quebec
  55. Longueuil, Quebec
  56. Montreal, Quebec
  57. Montreal, Quebec
  58. Pointe-Claire, Quebec
  59. Sherbrooke, Quebec
  60. St Jerome, Quebec
  61. St-Georges Ouest, Quebec
  62. St-Marc Des Carrieres, Quebec
  63. St. Lambert, Quebec
  64. Ste-foy, Quebec
  65. Regina, Saskatchewan
  66. Quebec,
  67. Quebec,
  68. Quebec,
  69. Rimouski,
  70. St-Gedeon Beauce,
  71. St. John's,
  72. St. John's,
  73. St. John's,
  74. Ayr, Ayrshire
  75. Sandy, Bedfordshire
  76. Peterborough, Cambs
  77. Thornhill, Cardiff
  78. Fowey, Cornwall
  79. Darlington, County Durham
  80. Darlington, County Durham
  81. Paignton, Devon
  82. Plymouth, Devon
  83. Bournemouth, Dorset
  84. Angus, Dundee
  85. Central Milton Keyne, England
  86. Lancaster, England
  87. Surrey, England
  88. Wishaw, Lanarkshire, England
  89. Leigh-on-sea, Essex
  90. nEWPORT, gWENT
  91. Letchworth, Hertfordshire
  92. Canterbury, Kent
  93. Whitstable, Kent
  94. Blackpool, Lancashire
  95. Spalding, Lincolnshire
  96. Bangor, Belfast, Northern Ireland
  97. Coatbridge, Scotland
  98. Glasgow, Scotland
  99. Frome, Somerset
  100. Stairfoot, Barnsley, South Yorkshire
  101. Weybridge, Surrey
  102. Leeds, West Yorkshire
  103. Sheffield, Yorkshire
  104. Aberdeen,
  105. Berkshire,
  106. Cambridge,
  107. Canterbury,
  108. Coventry,
  109. Coventry,
  110. Dorking,
  111. Dundee,
  112. Glasgow,
  113. Glasgow,
  114. Glasgow,
  115. Hertfordshire,
  116. Kent,
  117. Leeds,
  118. Newcastle-upon-Tyne,
  119. Newcastle-upon-Tyne,
  120. Nottingham,
  121. Rochdale,
  122. Shrewsbury,
  123. Stourbridge,
  124. Swanley,
  125. Swindon,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Hypertension, DyslipidemiaClinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
NCT00150384
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Huntsville, Alabama
  4. Little Rock, Arkansas
  5. Los Angeles, California
  6. Oakland, California
  7. Pico Rivera, California
  8. Bridgeport, Connecticut
  9. Washington, District of Columbia
  10. Washington, District of Columbia
  11. Aventura, Florida
  12. Gainesville, Florida
  13. Jacksonville, Florida
  14. Orlando, Florida
  15. Pensacola, Florida
  16. Vero Beach, Florida
  17. Athens, Georgia
  18. Atlanta, Georgia
  19. Atlanta, Georgia
  20. Atlanta, Georgia
  21. Atlanta, Georgia
  22. Augusta, Georgia
  23. Columbus, Georgia
  24. Columbus, Georgia
  25. Decatur, Georgia
  26. Lincolnton, Georgia
  27. Savannah, Georgia
  28. Chicago, Illinois
  29. Chicago, Illinois
  30. Maywood, Illinois
  31. Merrillville, Indiana
  32. Overland Park, Kansas
  33. Bossier City, Louisiana
  34. New Orleans, Louisiana
  35. New Orleans, Louisiana
  36. Shreveport, Louisiana
  37. Shreveport, Louisiana
  38. Baltimore, Maryland
  39. Baltimore, Maryland
  40. Columbia, Maryland
  41. Randallstown, Maryland
  42. Rockville, Maryland
  43. Westminster, Maryland
  44. Brockton, Massachusetts
  45. Wellesley Hills, Massachusetts
  46. Detroit, Michigan
  47. Detroit, Michigan
  48. Lansing, Michigan
  49. Livonia, Michigan
  50. Jackson, Mississippi
  51. Jackson, Mississippi
  52. Kansas City, Missouri
  53. Kansas City, Missouri
  54. St. Louis, Missouri
  55. St. Louis, Missouri
  56. St. Louis, Missouri
  57. Cherry Hill, New Jersey
  58. East Orange, New Jersey
  59. Elizabeth, New Jersey
  60. Hammonton, New Jersey
  61. South Bound Brook, New Jersey
  62. Voorhees, New Jersey
  63. Woodbury, New Jersey
  64. Brooklyn, New York
  65. Brooklyn, New York
  66. Buffalo, New York
  67. Mineola, New York
  68. Charlotte, North Carolina
  69. Greenville, North Carolina
  70. Monroe, North Carolina
  71. Monroe, North Carolina
  72. Winston-Salem, North Carolina
  73. Winston-Salem, North Carolina
  74. Cincinnati, Ohio
  75. Cincinnati, Ohio
  76. Cincinnati, Ohio
  77. Cincinnati, Ohio
  78. Dayton, Ohio
  79. Dayton, Ohio
  80. Maumee, Ohio
  81. Perrysburg, Ohio
  82. Bensalem, Pennsylvania
  83. Philadelphia, Pennsylvania
  84. Philadelphia, Pennsylvania
  85. Philadelphia, Pennsylvania
  86. Bamberg, South Carolina
  87. Charleston, South Carolina
  88. Clinton, South Carolina
  89. Mt. Pleasant, South Carolina
  90. Simpsonville, South Carolina
  91. Bartlett, Tennessee
  92. Jackson, Tennessee
  93. Beaumont, Texas
  94. Dallas, Texas
  95. Dallas, Texas
  96. Houston, Texas
  97. Houston, Texas
  98. Houston, Texas
  99. Emporia, Virginia
  100. Norfolk, Virginia
  101. Norfolk, Virginia
  102. Richmond, Virginia
  103. Richmond, Virginia
  104. Viginia Beach, Virginia
  105. Virginia Beach, Virginia
  106. Milwaukee, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
Official Title  ICMJE An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)
Brief Summary To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Hypertension
  • Dyslipidemia
Intervention  ICMJE Drug: Amlodipine/Atorvastatin
Study Arms  ICMJE Not Provided
Publications * Richard Hobbs FD, Gensini G, John Mancini GB, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P, Jenssen TG, da Silva PM; JEWEL Study Group. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):472-80. doi: 10.1097/HJR.0b013e32832b63f5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: May 26, 2006)		1250
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE September 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients who are above target LDL-C and BP who are eligible for treatment

Exclusion Criteria:

  • High liver enzymes
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00330785
Other Study ID Numbers  ICMJE A3841018
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP